14+ years and still sick and expelling biofilms - help

Full History of GI Issues – Trent Lapinski Onset and Early Course (≈2015–2017) Symptoms began around 2015–2016 with progressive gut dysfunction that has never fully resolved. Early features included recurrent nausea, abdominal pain, burning/toxic stools, and episodic gut motility shutdown. These episodes were accompanied by systemic inflammatory responses (swollen cervical/occipital lymph nodes, severe headaches, fatigue, and neurological fog). Motility would slow or stop entirely during flares, leading to toxin/fecal retention; clearance with laxatives reliably reduced systemic symptoms, establishing a clear pattern of gut-derived toxic burden driving the broader illness. Recurrent gastrointestinal infections were documented early, including C. difficile, enterohemorrhagic E. coli, H. pylori, and streptococcal species. These infections were often treatment-resistant or recurrent. A colonoscopy performed approximately 14 years prior (around 2012) is retrospectively considered a possible introduction point for a persistent, treatment-refractory biofilm-forming organism or community that has never been fully cleared. Confirmed Infections, Dysbiosis & Key Laboratory Findings • GI-MAP (29 Aug 2023) and subsequent abnormal stool studies repeatedly showed: ◦ High C. difficile toxins A/B ◦ Enterohemorrhagic E. coli ◦ Markedly elevated calprotectin (907 µg/g; normal <173) ◦ Elevated zonulin (940.4 ng/g; normal <175) indicating intestinal permeability ◦ Elevated secretory IgA • Positive Borrelia burgdorferi serology (IFA titer 80; IgG ImmunoBlot positive by IGX criteria, 11 May 2018) with ongoing clinical suspicion of chronic Lyme and possible co-infections (Bartonella considered on clinical grounds including historical striae). • Positive antibodies consistent with Aspergillus exposure. • Mildly elevated lipase (69 U/L) on at least one occasion, raising the question of concurrent biliary/pancreatic irritation. • Prior 4 mm gallbladder polyp (ultrasound 30 Aug 2023); no stones at that time, but function and possible later stone formation remain unevaluated. Genetic findings (Uforia panel) include impairments in detoxification (EPHX1, GSTP1), inflammation (CRP, IL6, TNF-α), and nutrient pathways (MTHFR, MTRR, FUT2), compounding the difficulty of clearing microbial toxins and managing inflammation. Dominant Pathophysiological Pattern The core cycle has remained consistent for nearly a decade: 1 Accumulation of microbial toxins / endotoxin / biofilm metabolites in the gut. 2 Gut motility shutdown (“gut paralysis”) when the toxic load rises. 3 Systemic spillover producing severe mast-cell activation syndrome (MCAS) flares — anaphylactic-like reactions with lymph-node swelling, neurological impairment, and extreme ice-pick headaches (unilateral, left or right temple/eye region). 4 Partial relief only after aggressive clearance of retained material (laxatives, binders). 5 Rapid re-accumulation, consistent with persistent biofilm reservoirs and/or continuous reseeding. Severe metabolic endotoxemia is a standing clinical concern. Visual Contrast Sensitivity testing has been positive on multiple occasions, supporting a biotoxin component (mold, Lyme-related, or microbial). Treatments Attempted A wide range of antimicrobial, anti-biofilm, and supportive strategies have been used, many of which produce temporary improvement followed by rebound or severe Herxheimer/MCAS reactions when biofilms are mobilized: • Conventional antibiotics and antiparasitic drugs • Herbal antimicrobials and antiparasitics • Berberine (most recent significant flare occurred after berberine use) • Lactoferrin • Phage therapy (bacteriophage preparations targeting a broad range of bacteria) • Ozone therapy (rectal, ear, and other routes) • Binders (charcoal and others) • Motility support (magnesium citrate and related agents) • Attempts at probiotic restoration (poorly tolerated; currently unable to take standard probiotics) • Biofilm-disrupting protocols • Supportive measures aimed at glutathione, antioxidants, and detoxification pathways Despite these interventions, complete eradication has not been achieved. Biofilm expulsion continues to trigger intense MCAS episodes and ice-pick headaches. Current Status and Ongoing Concerns (2025–2026) • Cyclical inflammatory/MCAS episodes remain tightly linked to gut toxin load and biofilm clearance events. • Gut paralysis still occurs when endotoxin/toxic burden rises. • Severe endotoxemia is an active clinical problem. • Ice-pick headaches (left or right) are a reliable marker of significant flares. • Persistent abnormal stool findings and clinical evidence of ongoing dysbiosis/inflammation. • Positive Aspergillus antibodies raise the possibility of chronic or intermittent fungal contribution. • Strong suspicion of occult dental/jaw cavitations or chronic oral-sinus reservoirs acting as continuous reseeding sources for the gut via the oral-gut axis. This remains an active investigative priority (CBCT imaging and biological dentistry evaluation planned/under consideration). • Hypothesis of a treatment-resistant, multi-species biofilm community possibly introduced or established around the time of the colonoscopy ~14 years ago continues to fit the clinical course better than any single pathogen model. Functional Impact Diet is severely restricted by MCAS and gut reactivity. Nutritional interventions are limited. Motility support and toxin clearance remain the most reliable short-term symptom modulators. Long-term goals center on identifying and eliminating hidden reservoirs (dental cavitations, residual biofilms, possible biliary contribution), restoring motility without triggering MCAS, and reducing endotoxin load enough to allow gradual reintroduction of supportive therapies that are currently intolerable.